On May 10, 2018 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported that three posters regarding the Company’s allogeneic off-the-shelf CAR-T product candidates and one poster associated with the Company’s technology will be presented at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting to be held from May 16 to 19, 2018, in Chicago, Illinois (Press release, Cellectis, MAY 10, 2018, file:///C:/Users/LENOVO/Downloads/20180510_PR_ASGCT.pdf [SID1234526472]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• Universal CAR T-Cells Targeting CS1 (UCARTCS1) for the Treatment of Multiple Myeloma

Agnès Gouble1, Roman Galetto1, Rohit Mathur3, Stephanie Filipe1, Isabelle ChionSotinel1,
Jing Yang3, Jin He3, Robert Z. Orlowski3, Sattva S. Neelapu3 and Julianne
Smith2
1Cellectis SA, 8 rue de la croix Jarry, 75013 Paris, France
2Cellectis, Inc., 430 East 29th Street, 10016 New York, NY
3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer
Center, 1515 Holcombe Blvd., Houston, TX 77030
Poster number: 130
Cancer – Targeted Gene & Cell Therapy I
Wednesday, May 16, 2018 at 5:30 PM – Stevens Salon C, D

• Repurposing endogenous immune pathways to improve chimeric antigen receptor T-cells potency

M. Sachdeva1, B. Busser1, S. Temburni1, A. Juillerat1, L. Poirot2, P. Duchateau2, J.
Valton1;
1Cellectis, Inc., New York, NY
2Cellectis, Paris, France
Poster number: 774
Cell Therapies III
Friday, May 18, 2018 at 5:45 PM – Stevens Salon C, D

• Engineering CAR T-Cells with an Integrated off Switch to Enhance Safety Performance

Alexandre Juillerat1, Diane Tkach1, Brian W. Busser1, Sonal Temburni1, Julien Valton1,
Aymeric Duclert2, Laurent Poirot2 and Philippe Duchateau2
1Cellectis, Inc., 430E, 29th Street, NYC, NY 10016
2Cellectis SA, 8 rue de la Croix Jarry, 75013 Paris, France
Poster number: 739
Cancer – Immunotherapy, Cancer Vaccines III
Friday, May 18, 2018 at 5:45 PM – Stevens Salon C, D
Presented by Allogene Therapeutics, Inc.:

• Cynomolgus macaque gene-edited CAR T-cell platform: towards a reliable in vivo allogeneic model to assess safety and Efficacy

Diego A. Vargas-Inchaustegui1, Rory Dai1, Alexandre Juillerat2, Christopher Do1, Kris
Poulsen1, Thomas Pertel1, Barbra Sasu1 1Allogene Therapeutics, Inc., South San Francisco, CA,
2Cellectis, Inc., New York, NY
Poster number: 131
Cancer – Targeted Gene & Cell Therapy I
Wednesday, May 16, 2018 at 5:30 PM – Stevens Salon C, D

Abstracts are available on the ASGCT (Free ASGCT Whitepaper) website. The 4 posters to be presented at the 2018 ASGCT (Free ASGCT Whitepaper) Annual Meeting will be available on the Cellectis website after May 19, 2018.